findmyKOL

Nathan Radcliffe, MD

Enriched profile

Associate Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai · Icahn School of Medicine at Mount Sinai

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyOphthalmologyFocusGlaucoma
Active KOLfindmyKOL type: EliteLatest publication2025Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Nathan Radcliffe is Associate Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai at Icahn School of Medicine at Mount Sinai. OpenAlex indexes 177 publications with 2,726 citations (h-index 28); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

Nathan Radcliffe, MD, is Associate Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai. The public record shows 177 publications with 2,726 citations (h-index 28), centered on Glaucoma. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 45 companies.

  • Most recent indexed publication: 2025 · Clinical ophthalmology (Auckland, N.Z.)
  • Top research focus: Glaucoma
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 45 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Glaucoma3 trialsComa3 trialsHypertension2 trialsOcular Hypertension2 trialsCataract1 trial

Research focus

OpenAlex concept fingerprint
Glaucoma

Drugs & molecules

across trials, industry payments and publications
Dexycugeneric · DexamethasoneClinical trials—Industry payments14Publications1Xelprosgeneric · LatanoprostClinical trials—Industry payments5Publications1Durystageneric · BimatoprostClinical trials—Industry payments295Publications—Rocklatangeneric · Latanoprost / netarsudilClinical trials—Industry payments232Publications—Miebogeneric · PerfluorohexyloctaneClinical trials—Industry payments81Publications—Vyzultageneric · Latanoprostene bunodClinical trials—Industry payments81Publications—Tyrvayageneric · VareniclineClinical trials—Industry payments73Publications—Vuitygeneric · PilocarpineClinical trials—Industry payments71Publications—Rhopressageneric · NetarsudilClinical trials—Industry payments70Publications—Xiidrageneric · LifitegrastClinical trials—Industry payments69Publications—Cequageneric · CyclosporineClinical trials—Industry payments35Publications—BrimonidineClinical trials—Industry payments26Publications—

Works with

trial sponsors and companies reporting payments
Alcon Vision LLCClinical trials—Industry payments467Abbvie Inc.Clinical trials—Industry payments236Allergan, Inc.Clinical trials—Industry payments199Bausch & Lomb Americas Inc.Clinical trials—Industry payments163Sight Sciences, Inc.Clinical trials—Industry payments117Oyster Point Pharma, Inc.Clinical trials—Industry payments73Glaukos CorporationClinical trials—Industry payments66New World Medical,Inc.Clinical trials—Industry payments46Reichert, Inc.Clinical trials—Industry payments36Aerie Pharmaceuticals, Inc.Clinical trials—Industry payments27Novartis Pharmaceuticals CorporationClinical trials—Industry payments22Alcon Research LLCClinical trials—Industry payments20EyePoint Pharmaceuticals US, Inc.Clinical trials—Industry payments18Dompe US, Inc.Clinical trials—Industry payments14Ivantis, IncClinical trials—Industry payments11Bausch & Lomb, a division of Bausch Health US, LLCClinical trials—Industry payments10BioTissue Holdings, Inc.Clinical trials—Industry payments10Kala Pharmaceuticals, Inc.Clinical trials—Industry payments10Harrow Eye, LLCClinical trials—Industry payments9Sun Pharmaceutical Industries Inc.Clinical trials—Industry payments8Tarsus Pharmaceuticals, Inc.Clinical trials—Industry payments8Carl Zeiss Meditec, Inc.Clinical trials—Industry payments7Beaver-Visitec International, Inc.Clinical trials—Industry payments6Iridex CorporationClinical trials—Industry payments6Carl Zeiss Meditec USA, Inc.Clinical trials—Industry payments5Eyevance Pharmaceuticals LLCClinical trials—Industry payments5Rayner Intraocular Lenses LimitedClinical trials—Industry payments4Alimera Sciences, Inc.Clinical trials—Industry payments3Thea Pharma Inc.Clinical trials—Industry payments3RxSight IncClinical trials—Industry payments2

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
177publications

Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.

2,726citations

Total citations across indexed works.

28h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials ↓
45companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 16 Oct 2026

45 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    84%
    Prostaglandin Analog36.2%
    Latanoprost79%Lumigan18%Iyuzeh2%Travoprost1%
    Part D<11 patients
    Carbonic Anhydrase Inhibitor21.8%
    Dorzolamide-Timolol65%Simbrinza11%Acetazolamide Er9%Dorzolamide Hcl9%Brinzolamide4%Acetazolamide2%
    Part D≥504 patients

    + 8 more classes in this area

  • Cancer & immunology

    4.5%
    Calcineurin inhibitor4.5%
    Restasis91%Cyclosporine7%Vevye2%
    Part D<11 patients
  • Cardiovascular

    4.3%
    Beta blocker4.3%
    Timolol Maleate90%Betaxolol Hcl10%
    Part D≥145 patients
All 7 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)3.5% facility · 96.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/nathan-radcliffe-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • Other

    drradcliffe.com

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →drradcliffe.com ↗
  • X / Twitter

    x.com/n8radcliffe

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/glaucomatoday/p/C33DcAKtEjB

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • Other

    eyetube.net/podcasts/gt-the-podcast

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyetube.net ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • Glaucomatoday.com

    Twitter/X: @n8radcliffe

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →glaucomatoday.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.